Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +34.12%
#2 Cortex Cortex +31.95%
#3 DexNet DexNet +23.19%
#4 Akedo Akedo +21.42%
#5 Pons Pons +17.60%
#6 wojak wojak +15.79%
#7 OpenEden OpenEden +15.43%
#8 APEX APEX +13.93%
#9 TDCCP TDCCP +11.17%
#10 MANTRA MANTRA +10.66%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
D&D Pharmatech D&D Pharmatech

D&D Pharmatech

347850
शेयरों में रैंक #7194
Established in 2014 and headquartered in Seongnam-si, South Korea, D&D... Established in 2014 and headquartered in Seongnam-si, South Korea, D&D Pharmatech Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing pharmaceutical treatments in both South Korea and the United States. The company's robust drug pipeline includes several candidates currently in clinical development: Phase II Trials: NLY01-PD, NLY01-AD, and NLY01-D are being investigated for their efficacy against Parkinson's disease, Alzheimer's disease, and type 2 diabetes, respectively. Completed Phase IIa Trial: P4M01 has successfully finished its Phase IIa study for the treatment of periodontal disease. Phase I Trials: A significant portion of its portfolio is in early human trials, encompassing DD01 for obesity, diabetes, and nonalcoholic steatohepatitis (NASH); TLY012, targeting NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03, focused on Parkinson's disease, Alzheimer's disease, and neuroinflammation; PMI04, addressing Parkinson's disease, Alzheimer's disease, ALS, and depression; and PMI05 and PMI06, both exploring applications in oncology and immuno-oncology. Beyond the clinical stage, D&D Pharmatech is actively developing a range of preclinical compounds. These include NLY03 for stroke and Parkinson's disease; DD03 for obesity and NASH; TLY014, designed to modulate the tumor microenvironment; PMI31 for various cancer types; and VT01 for Parkinson's disease. Further research involves NLY02 for Parkinson's and Alzheimer's diseases; NLY12 for type 2 diabetes and obesity; DD02 for type 2 diabetes; PMI21 for prostate cancer; and PMI07 for oncology and fibrotic conditions. Additionally, the company strategically applies big data analytics to enhance its central nervous system drug research and diagnostics initiatives.
शेयर मूल्य
$38.45
मार्केट कैप
$1.68B
बदलाव (1 दिन)
-1.24%
बदलाव (1 वर्ष)
50.36%
देश
KR
व्यापार D&D Pharmatech (347850)

श्रेणी

Healthcare
D&D Pharmatech (347850) के लिए P/S अनुपात
2026 को P/S अनुपात TTM: 0
D&D Pharmatech की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/S अनुपात (TTM) 0 है। 2026 के अंत में, कंपनी का P/S अनुपात 0 था।
D&D Pharmatech के लिए 2026 से 2026 तक P/S अनुपात का इतिहास
हर वर्ष के अंत में P/S अनुपात
वर्ष P/S अनुपात परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए P/S अनुपात
कंपनी P/S अनुपात P/S अनुपात में अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH